AQSTAquestive Therapeutics, Inc.
Price
-23%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, a flag to check, growing in the filings, the market with it.
Charts
As reported to the SEC, without any scoring.
Aquestive Therapeutics, Inc. (AQST) reported revenue of $14M in Q2 2026 (quarter ended Jun 30, 2026), up 38% from the same quarter a year earlier. That came with a gross margin of 71% and net loss of $23M. For the full year FY2025, revenue was $45M (−23% year on year) and net income −$84M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 29, 2026, Aquestive Therapeutics, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has elected Richard J. Daly as a director of the Company, effective October 14, 2026.Director or officer change · Form 8-K
- Sep 17, 2026On September 17, 2026, the Company issued a press release announcing it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis.Regulation FD disclosure · Form 8-K
- Aug 11, 2026Aquestive Therapeutics Reports Second Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #37 of 41 by RyuScore